Filtern
Volltext vorhanden
- ja (4)
Gehört zur Bibliographie
- ja (4)
Dokumenttyp
Sprache
- Englisch (4)
Schlagworte
- aspergillus fumigatus (2)
- Alpha therapy (1)
- Aspergillus fumigatus (1)
- Autoimmune diseases (1)
- Bone marrow transplantantation (1)
- CD11b+ myeloid cells (1)
- DNA transcription (1)
- Expression (1)
- Factor receptor (1)
- Graft-versus-leukemia (1)
- Regulatory-cells (1)
- Rheumatoid arthritis (1)
- Suppression (1)
- Tumor-necrosis-factor (1)
- aspergillosis (1)
- conditional promoter replacement (1)
- corticosteroids and cyclophosphamide (1)
- fungal pathogens (1)
- gene family targeting (1)
- gene regulation (1)
- immune cell recruitment (1)
- methionine (1)
- nutrients (1)
- sulfates (1)
- sulfur (1)
- transcription factors (1)
- virulence (1)
Institut
- Institut für Molekulare Infektionsbiologie (2)
- Medizinische Klinik und Poliklinik II (2)
- Abteilung für Molekulare Innere Medizin (in der Medizinischen Klinik und Poliklinik II) (1)
- Graduate School of Life Sciences (1)
- Institut für Virologie und Immunbiologie (1)
- Julius-von-Sachs-Institut für Biowissenschaften (1)
- Pathologisches Institut (1)
- Rudolf-Virchow-Zentrum (1)
Donor CD4\(^+\)Foxp3\(^+\) regulatory T cells (T reg cells) suppress graft-versus-host disease (GvHD) after allogeneic hematopoietic stem cell transplantation (HCT allo-HCT]). Current clinical study protocols rely on the ex vivo expansion of donor T reg cells and their infusion in high numbers. In this study, we present a novel strategy for inhibiting GvHD that is based on the in vivo expansion of recipient T reg cells before allo-HCT, exploiting the crucial role of tumor necrosis factor receptor 2 (TNFR2) in T reg cell biology. Expanding radiation-resistant host T reg cells in recipient mice using a mouse TNFR2-selective agonist before allo-HCT significantly prolonged survival and reduced GvHD severity in a TNFR2-and T reg cell-dependent manner. The beneficial effects of transplanted T cells against leukemia cells and infectious pathogens remained unaffected. A corresponding human TNFR2-specific agonist expanded human T reg cells in vitro. These observations indicate the potential of our strategy to protect allo-HCT patients from acute GvHD by expanding T reg cells via selective TNFR2 activation in vivo.